FS102

FS102 is a selective Fc fragment with antigen binding (Fcab) that targets HER2 with a KD value of 0.8 nM. FS102 induces the degradation of HER2, activates Caspase 3/7 and disrupts the integrity of the cell membrane, triggering apoptosis of tumor cells. FS102 is promising for research of cancers such as breast cancer, gastric cancer, and colorectal cancer[1][2].

BMS-986186

12352203

Caspase; EGFR

Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer

FS(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)(S(=S)([S](=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S)=S

[1]Batey S, et al. Abstract B123: Preclinical evaluation of FS102: A HER2-specific Fcab with a novel mechanism of action[J]. Molecular Cancer Therapeutics, 2013, 12 (11_Supplement) : B123-B123.|[2]Leung K M, et al. A HER2-specific modified Fc fragment (Fcab) induces antitumor effects through degradation of HER2 and apoptosis[J]. Molecular Therapy, 2015, 23 (11) : 1722-1733.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991235/

Inhibitory Antibodies

Phase 1

Caspase 3; Caspase 7; ErbB2/HER2